跳至主要内容
临床试验/NCT04203810
NCT04203810已完成不适用

Effectiveness and Tolerability of Ectoin® Mouth and Throat Spray Althaea Honey (ERS09) Compared to Saline Spray in Patients Suffering From Sore Throat Due to Acute Pharyngitis and Dry Cough

Bitop AG13 个研究点 分布在 1 个国家目标入组 194 人开始时间: 2020年1月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Bitop AG
入组人数
194
试验地点
13
主要终点
Change of daily symptom score

研究概览

简要总结

The aim of this multicentre, actively controlled, randomized, open label, parallel group, prospective, comparator study is to collect data on the clinical effectiveness and tolerability of the medical device ERS09 compared to a well-established comparator spray in the symptomatic treatment of sore throat due to acute pharyngitis and dry cough.

详细描述

The aim of this study is to collect data on the clinical effectiveness and tolerability of Ectoin® Mouth and Throat Spray Althaea Honey (ERS09) compared to the well-established comparator spray EMSER® Hals- und Rachenspray (both medical devices) in the symptomatic treatment of sore throat due to acute pharyngitis and dry cough.

The principle mode of action of ectoine is based on the physical interaction of the compatible solute with water and the resulting stabilizing effects of the ectoine hydro complex on the epithelial tissue treated. Althaea has so-called mucilaginous effects, that means generally a shielding of the irritated mucus membranes by thin polysaccharide layers. Such mucilaginous polymer layers lead to rehydration, coating of peripheral sensory receptors, and therefore to a reduction of throat irritation and dry coughing. Honey acts predominantly as demulcent with its viscous liquid constitution based on mainly fructose and glucose. The combination of all three substances may result in a multi-modal treatment of the symptoms of sore throat and dry cough.

Patients will be randomly assigned to one of the following treatment groups:

  • treatment with ERS09
  • treatment with comparator (EMSER® Hals- und Rachenspray)

Patients' symptoms will be documented by the physician in investigator questionnaires at visits 1, 2 and 3. At visit 1 the patients will receive a patient diary for daily documentation of their symptoms. In addition, patients and investigators will be asked to evaluate the overall effectiveness and tolerability of ERS09 spray at visit 3.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP)/ISO14155 guidelines and local regulation prior to participation in the trial
  • Individuals regardless of gender 12 years old or older
  • Patients with sore throat due to acute pharyngitis and dry cough, both with an onset of symptoms no more than 72 hours prior to Visit 1
  • Sore Throat Pain Intensity Score ≥ 40 mm (measured on a 100 mm visual analogue scale [VAS])

排除标准

  • Hypersensitivity to Ectoin, Althaea off., Honey or any of the other ingredients of the ERS09 or the comparator
  • Fructose intolerance or glucose-galactose malabsorption
  • Pregnant or breast-feeding women
  • Suspected bacterial pharyngitis
  • Individuals younger than 12 years
  • Symptoms since more than 72 hours
  • Use of any pain or cough medication (i.e. analgesic/ anti-pyretic/ anti-inflammatory or mucolytic/ expectorant/ antitussive) within 24 hours preceding enrolment in the study
  • Oral lesions or oral surgical procedures within 1 month prior to enrolment in the study
  • Patients for who the Investigator believes will not comply with the study protocol (e.g. patients with drug abuse or with a history of a serious psychiatric disorder as well as patients unwilling to give informed consent or to abide by the requirements of the protocol)

结局指标

主要结局

Change of daily symptom score

时间窗: 1 day

Baseline adjusted daily change of patient's assessment of total symptom score (patient diary)

Change of mean total symptom score

时间窗: 7 days

Baseline adjusted mean change of patient's assessment of total symptom score (patient diary) averaged over 7 treatment days

次要结局

  • Adverse events (AE) and serious adverse events (SAE) during treatment phase(7 +/- 2 days)

研究者

发起方
Bitop AG
申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验